Management of Toxic Epidermal Necrolysis

Introduction to Treatment Options

• The British Journal of Dermatology recommends against the routine use of IV steroids in toxic epidermal necrolysis due to conflicting evidence on efficacy and concerns about increased infection risk 1, 2, 3

Evidence Assessment

• Systemic corticosteroids have historically been used in TEN management, but there is insufficient evidence to support their routine use, with the British Journal of Dermatology emphasizing the need for more research 2
• A meta-analysis suggested a potential survival benefit with glucocorticosteroids, but this was significant in only one of three statistical analyses, according to the British Journal of Dermatology 1
• The British Journal of Dermatology reports that retrospective analysis of EuroSCAR data showed lower mortality in German patients treated with corticosteroids compared to supportive care alone 2

Concerns with Corticosteroid Use

• There is significant concern that systemic corticosteroids may increase infection risk in TEN patients, as reported by the British Journal of Dermatology 1, 4
• The British Journal of Dermatology notes that a retrospective case series reported two deaths in patients treated with prednisolone 1

Alternative Treatment Options

• High-quality, multidisciplinary supportive care remains the priority in TEN management, according to the British Journal of Dermatology 3
• The British Journal of Dermatology suggests that ciclosporin and TNF-α inhibitors have shown promise in recent studies, with ciclosporin (3 mg/kg daily for 10 days, then tapered) showing effectiveness with no deaths despite SCORTEN-predicted mortality of 2.75/29 in one study 2, 5
• The British Journal of Dermatology reports that intravenous immunoglobulin (IVIg) has shown mixed results, with some studies showing benefit and others showing no improvement in survival compared to supportive care 2, 6, 7

Special Considerations

• In pediatric populations, TEN has a lower mortality rate, so prevention of long-term complications becomes extremely important, as noted by the British Journal of Dermatology 1, 4
• The British Journal of Dermatology notes that ocular complications are common in TEN, and there is conflicting data on whether systemic corticosteroids help limit ocular disease 1, 8
• Respiratory complications can be severe and may not correlate with the extent of epidermal detachment, according to the British Journal of Dermatology 9, 10

Systemic Corticosteroids in TEN Patients Receiving IVIG

Evidence Assessment for Corticosteroid Use in TEN

• Retrospective analysis of EuroSCAR data showed lower mortality in German patients (but not French patients) treated with corticosteroids compared to supportive care alone, with some studies investigating pulsed IV and high-dose corticosteroids reporting decreased mortality compared to SCORTEN predictions 11

Clinical Decision Algorithm

• Ocular complications, such as those requiring topical corticosteroid drops (e.g., nonpreserved dexamethasone 0.1%) supervised by an ophthalmologist, may be considered in patients with significant ocular involvement, with conflicting data on whether systemic corticosteroids help limit ocular disease 12, 13

Steroid Dosing for Toxic Epidermal Necrolysis

Evidence Assessment for Corticosteroid Use

• The UK guidelines recommend against routine use of systemic corticosteroids in toxic epidermal necrolysis due to conflicting evidence on efficacy and significant concerns about increased infection risk 14, 15
• No randomized controlled trials exist - all available evidence comes from retrospective case series with significant methodological limitations 14, 15
• Retrospective EuroSCAR data showed lower mortality in German patients (but not French patients) treated with corticosteroids compared to supportive care alone, highlighting geographic and methodological inconsistencies 14, 15

Infection Risk Concerns

• The primary concern with systemic corticosteroids is increased infection risk, which is particularly dangerous in TEN patients who already have compromised skin barrier function 14, 15

If Corticosteroids Are Used Despite Guidelines

• Methylprednisolone 40-80 mg daily (approximately 0.8-1.5 mg/kg/day for average adult) with rapid tapering over 7-10 days once disease progression arrests 15
• IV dexamethasone 100 mg once daily for 3 days in combination with cyclophosphamide (though this regimen showed inferior outcomes to cyclosporin) 15
• Methylprednisolone 1-1.5 mg/kg/day in combination with other agents 15

Critical Clinical Pitfalls

• Do not use corticosteroids as monotherapy without considering alternatives like cyclosporin or IVIG, given the infection risk and lack of proven benefit 14, 15
• If corticosteroids are initiated, use the shortest possible duration with rapid tapering once disease progression arrests (typically 7-10 days total) 15
• Monitor closely for infections with daily smears of skin and mucous membranes, as corticosteroids blunt the febrile response 16

Systemic Corticosteroid Use and Preferred Alternatives in Toxic Epidermal Necrolysis

1. Guideline Stance on Systemic Corticosteroids

• The 2016 UK guideline (British Journal of Dermatology) recommends against routine intravenous corticosteroids for TEN, citing insufficient evidence of benefit and a significant infection risk. This recommendation is based on the highest‑quality guideline evidence available. 17
• Systemic corticosteroids are not routinely recommended for TEN because of conflicting efficacy data and the potential for increased infections; however, early high‑dose methylprednisolone (within 72 h of onset) may be considered in selected cases. 17

2. Preferred Immunomodulatory Therapy

• Cyclosporine is recommended as the first‑line immunomodulatory agent when supportive care alone is inadequate, because it has stronger supporting evidence than corticosteroids. 17
• Dosage: 3 mg/kg per day for 10 days, followed by a taper over approximately one month. 17
• Evidence of benefit: Multiple studies demonstrate a reduction in mortality compared with SCORTEN‑predicted rates; one cohort reported 0 deaths despite a predicted mortality of 2.75 % (2.75/29 patients). 17
• Mechanistic advantage: Cyclosporine targets T‑cell‑mediated pathology without the broad immunosuppression and infection risk associated with corticosteroids. 17

3. Core Supportive‑Care Measures (Universal Recommendations)

• Immediate discontinuation of all suspected culprit drugs is the single most critical intervention. 17
• Transfer to a specialized burn centre or intensive‑care unit should occur within hours for patients with >10 % body‑surface‑area involvement; delayed transfer markedly increases mortality. 17
• SCORTEN calculation within 24 h is required to estimate mortality risk (scores 0–7 correspond to 1 %–99 % predicted mortality). 17

4. Infection‑Prevention Strategies

• Prophylactic systemic antibiotics are not recommended, as they promote resistant organism colonisation (e.g., Candida) without improving outcomes. 17
• Targeted antimicrobial therapy should be initiated only when clinical signs of infection are present (e.g., altered mental status, hypotension, oliguria, desaturation, increased skin pain, rising inflammatory markers). 17

5. Practical Pitfalls to Avoid

• Do not use corticosteroids as monotherapy without considering alternatives such as cyclosporine, given the lack of proven benefit and heightened infection risk. 17
• Do not delay transfer to specialized care while debating immunomodulatory options; timely multidisciplinary supportive care saves more lives than any specific drug. 17
• Do not employ prophylactic antibiotics even when corticosteroids are administered, as this compounds infection risk. 17

6. Evidence Hierarchy Summary

• The 2016 UK guideline represents the most comprehensive systematic review of available data and explicitly advises against routine corticosteroid use, reflecting a high level of evidence (guideline‑grade recommendation). 17
• The evidence hierarchy favors cyclosporine over corticosteroids for immunomodulation beyond supportive care, based on multiple observational studies showing mortality benefit. 17

Systemic Corticosteroid Use in Stevens‑Johnson Syndrome: Evidence‑Based Guidance

Recommendations (British Association of Dermatology)

Evidence Base for Corticosteroids

Primary Safety Concern: Infection Risk

Preferred Alternative Immunomodulatory Therapy (Cyclosporine)

Special Situations

Immune Checkpoint Inhibitor–Induced SJS/TEN

Pediatric Patients